Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 20/20 | 0.81 |
| ▸ | MMP2 | P08253 | 5/20 | 0.64 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.62 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.62 |
| ▸ | MMP3 | P08254 | 2/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7647602 | 1.00 | BMP1 (0.81) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL5760686 | 0.90 | BMP1 (0.69) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL6428360 | 0.90 | BMP1 (1.00) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL6429734 | 0.88 | BMP1 (0.82) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL6430549 | 0.87 | BMP1 (0.73) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL27567205 | 0.87 | BMP1 (0.74) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL27567210 | 0.87 | BMP1 (0.74) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL6179694 | 0.86 | BMP1 (0.64) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL6428262 | 0.86 | BMP1 (0.78) | BMP1MMP2PDE4APDE4BPDE4C | |
| SCHEMBL27567224 | 0.86 | BMP1 (0.78) | BMP1MMP2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| EP-1373231-B1 | 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-6831088-B2 | Wound healing agents; antiscarring agents | PFIZER INC. | 2004-12-14 | — | — | US | disclosed |
| EP-1240152-B1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040058917-A1 | 3-Heterocyclylpropanohydroxamic acid PCP inhibitors | FISH PAUL VINCENT (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1373231-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID PCP INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6645993-B2 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | WARNER-LAMBERT COMPANY | 2003-11-11 | — | — | US | disclosed |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | disclosed |
| CN-1423638-A | Oxazolyl hydroxamic acids as procollagen C-protease inhibitors | PFIZER LTD (US) | 2003-06-11 | — | — | CN | disclosed |
| US-20020187979-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | FISH PAUL VINCENT (GB) | 2002-12-12 | — | — | US | disclosed |
| WO-2002079175-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID PCP INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | BMP1 166/4885MMP2 16/4885PDE4A 2310/4885 |
| US-20040058917-A1 | 3-Heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, FAP, PREP | BMP1 77/4885MMP2 34/4885PDE4A 1841/4885 |
| US-20020187979-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | MMP1, CPA1, PAH | BMP1 26/4885MMP2 28/4885PDE4A 2221/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | BMP1 79/4885MMP2 11/4885PDE4A 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.